Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor.
Epistemonikos ID: d48291679760606e53f4eb0592926f153a0f2aac
First added on: May 15, 2024